Expression analysis and specific blockade of the receptor for human thymic stromal lymphopoietin (TSLP) by novel antibodies to the human TSLPRα receptor chain

Cytokine

Volumn 61, Issue 2, 2013, Pages 546-555

  Borowski, Andreas ^a   Vetter, Tina ^a   Kuepper, Michael ^b   Wohlmann, Andreas ^a   Krause, Sebastian ^c   Lorenzen, Thomas ^a   Virchow, Johann Christian ^b   Luttmann, Werner ^d   Friedrich, Karlheinz ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c INVIGATE GmbH   (Germany)

^d ImmunoTools GmbH   (Germany)

Author keywords

Asthma bronchiale; Cytokine receptors; Inhibitory antibody; Thymic stromal lymphopoietin; TSLP

Indexed keywords

INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 7 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; RECEPTOR; STAT3 PROTEIN; THYMIC STROMAL LYMPHOPOIETIN; THYMIC STROMAL LYMPHOPOIETIN RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATOPY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; IMMUNIZATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RECEPTOR BLOCKING; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS; FLOW CYTOMETRY; HEK293 CELLS; HUMANS; LIGANDS; MICE; MICE, INBRED BALB C; PROTEIN BINDING; PROTEIN DENATURATION; RECEPTORS, CYTOKINE; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SOLUBILITY;

MURINAE;

EID: 84873158356     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.10.025     Document Type: Article

References (43)

1. + B cells and produces a novel growth factor affecting B and T lineage cells. Exp Hematol 1994, 22:321-328.
2. Ray R.J., Furlonger C., Williams D.E., Paige C.J. Characterization of thymic stromal derived lymphopoietin (TSLP) in murine B cell development in vitro. Eur J Immunol 1996, 26:10-16.
3. Tonozuka Y., Fujio K., Sugiyama T., Nosaka T., Hirai M., Kitamura T. Molecular cloning of a human novel type I cytokine receptor related to delta1/TSLPR. Cytogenet Cell Genet 2001, 93:23-25.
4. Quentmeier H., Drexler H.G., Fleckenstein D., Zaborski M., Armstrong A., Sims J.E., et al. Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation. Leukemia 2001, 15:1286-1292.
5. Reche P.A., Soumelis V., Gorman D.M., Clifford T., Liu M.R., Travis M., et al. Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J Immunol 2001, 167:336-343.
6. Pandey A., Ozaki K., Baumann H., Levin S.D., Puel A., Farr A.G., et al. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nature Immunol 2000, 1:59-64.
7. Park L.S., Martin U., Garka K., Gliniak B., Di Santo J.P., Muller W., et al. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: formation of a functional heteromeric complex requires interleukin 7 receptor. J Exp Med 2000, 192:659-670.
8. + T cells. J Immunol 2007, 178:6720-6724.
9. Sebastian K., Borowski A., Kuepper M., Friedrich K. Signal transduction around thymic stromal lymphopoietin (TSLP) in atopic asthma. Cell Commun Signal 2008, 25:5.
10. Wohlmann A., Sebastian K., Borowski A., Krause S., Friedrich K. Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function. Biol Chem 2010, 391:181-186.
11. Zhou B., Comeau M.R., De Smedt T., Liggitt H.D., Dahl M.E., Lewis D.B., et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nature Immunol 2005, 6:1047-1053.
12. Al-Shami A., Spolski R., Kelly J., Keane.-Myers A., Leonard W.J. A role for TSLP in the development of inflammation in an asthma model. J Exp Med 2005, 202:829-839.
13. Ying S., O'Connor B., Ratoff J., Meng Q., Mallett K., Cousins D., et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol 2005, 174:8183-8190.
14. Ying S., O'Connor B., Ratoff J., Meng Q., Fang C., Cousins D., et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol 2008, 181:2790-2798.
15. Shi L., Leu S.W., Xu F., Zhou X., Yin H., Cai L., et al. Local blockade of TSLP receptor alleviated allergic disease by regulating airway dendritic cells. Clin Immunol 2008, 129:202-210.
16. Lee H.-C., Ziegler S.F. Inducible expression of the proallergic cytokine thymic stromal lymphopoietin in airway epithelial cells is controlled by NFkappaB. Proc Natl Acad Sci USA 2007, 104:914-919.
17. Allakhverdi Z., Comeau M.R., Jessup H.K., Yoon B.R., Brewer A., Chartier S., et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 2007, 204:253-258.
18. Nagata Y., Kamijuku H., Taniguchi M., Ziegler S., Seino K. Differential role of thymic stromal lymphopoietin in the induction of airway hyperreactivity and Th2 immune response in antigen-induced asthma with respect to natural killer T cell function. Int Arch Allergy Immunol 2007, 144:305-314.
19. Soumelis V., Reche P.A., Kanzler H., Yuan W., Edward G., Homey B., et al. Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. Nature Immunol 2002, 3:673-680.
20. Krause S., Behrends J., Borowski A., Lohrmann J., Lang S., Myrtek D., et al. Blockade of interleukin-13-mediated cell activation by a novel inhibitory antibody to human IL-13 receptor alpha1. Mol Immunol 2006, 43:1799-1807.
21. Kammer W., Lischke A., Moriggl R., Groner B., Ziemiecki A., Gurniak C.B., et al. Homodimerization of interleukin-4 receptor α chain can induce intracellular signalling. J Biol Chem 1996, 271:23634-23637.
22. The T.H., Feltkamp T.E. Conjugation of fluorescein isothiocyanate to antibodies. II. A reproducible method. Immunology 1970, 18:875-881.
23. Winkler C., Denker K., Wortelkamp S., Sickmann A. Silver- and Coomassie-staining protocols: detection limits and compatibility with ESI MS. Electrophoresis 2007, 28:2095-2099.
24. Zhang F., Huang G., Hu B., Song Y., Shi Y. A soluble thymic stromal lymphopoietin (TSLP) antagonist, TSLPR-immunoglobulin, reduces the severity of allergic disease by regulating pulmonary dendritic cells. Clin Exp Immunol 2011, 164:256-264.
25. Elliott M.J., Maini R.N. Anti-cytokine therapy in rheumatoid arthritis. Baillière's Clinical Rheumatology 1995, 9:633-652.
26. Jelusic M., Lukic I.K., Batinic D. Biological agents targeting interleukin-18. Drug News Perspect 2007, 20:485-494.
27. Mueller T.D., Zhang J.L., Sebald W., Duschl A. Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim Biophys Acta 2002, 1592:237-250.
28. Puel A., Ziegler S.F., Buckley R.H., Leonard W.J. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nature Genet 1998, 20:394-397.
29. Kikuchi K., Lai A.Y., Hsu C.-L., Kondo M. IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF. J Exp Med 2005, 201:1197-1203.
30. Herzog S., Reth M., Jumaa H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nature Rev Immunol 2009, 9:195-205.
31. Nakamura H., Takamori S., Fujii T., Ono M., Yamana H., Kuwano M., et al. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. Cancer Lett 2005, 230:33-46.
32. Bull Phelps S.L., Schorge J.O., Peyton M.J., Shigematsu H., Xiang L.L., Miller D.S., et al. Implications of EGFR inhibition in ovarian cancer cell proliferation. Gynecol Oncol 2008, 109:411-417.
33. Yang H., Jager M.J., Grossniklaus H.E. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci 2010, 51:2835-2842.
34. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992, 89:4285-4289.
35. Miyata M., Nakamura Y., Shimokawa N., Ohnuma Y., Katoh R., Matsuoka S., et al. Thymic stromal lymphopoietin is a critical mediator of IL-13-driven allergic inflammation. Eur J Immunol 2009, 39:3078-3083.
36. Harvey R.C., Mullighan C.G., Chen I.M., Wharton W., Mikhail F.M., Carroll A.J. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration ofIKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115:5312-5321.
37. Yoda A., Yoda Y., Chiaretti S., Bar-Natan M., Mani K., Rodig S.J., et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010, 107:252-257.
38. Ensor H.M., Schwab C., Russell L.J., Richards S.M., Morrison H., Masic D., et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 2011, 117:2129-2136.
39. Olkhanud P.B., Rochman Y., Bodogai M., Malchinkhuu E., Wejksza K., Xu M., et al. Thymic stromal lymphopoietin is a key mediator of breast cancer progression. J Immunol 2011, 186:5656-5662.
40. Müerköster S., Wegehenkel K., Arlt A., Witt M., Sipos B., Kruse M.L., et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1β. Cancer Res 2004, 64:1331-1337.
41. Ohara M., Yamaguchi Y., Matsuura K., Murakami S., Arihiro K., Okada M. Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol Immunother 2009, 58:441-447.
42. De Monte L., Reni M., Tassi E., Clavenna D., Papa I., Recalde H., et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011, 208:469-478.
43. Li H., Zhao H., Yu J., Su Y., Cao S., An X., et al. Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin. Cancer Immunol Immunother 2011, 60:1587-1596.